At the end of April, biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the FDA had accepted the resubmission of its Biologics License Application (BLA) for a drug called Kevzara.
May 22, 2017 at 11:16PM
from Mark Collins
Featured Post
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA)
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA) Please click the li...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment